Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : Junshi Biosciences and Lonza Partner to Produce a Neutralizing Antibody Tackling COVID-19

07/13/2020 | 09:06am EDT
  • Junshi Biosciences developing therapies for COVID-19 in collaboration with a number of global partners
  • Junshi Biosciences' first SARS-CoV-2 neutralizing antibody, expressed using Lonza's GS Xceed® Gene Expression System, entered clinical trials in China
  • Track record of the GS Xceed expression system, together with Lonza's technical and regulatory expertise cited as critical enablers for this program

Quote from Jean-Christophe Hyvert, Chief Commercial Officer, Lonza:

'With dozens of commercial products launched using the GS Exceed Gene Expression System, the first clinical trial of neutralizing antibody for COVID-19 in China using our technology is a key milestone for Lonza. Coming off the back of Junshi's approval for the first Chinese anti-PD-1 therapy, Junshi is setting the standard for biologics innovation in China and by choosing GS Xceed they have laid a solid foundation for success.'

Quote from Dr. Feng Hui, Chief Operation Officer of Junshi Biosciences:

'Time to market is critical in this campaign against COVID-19. By leveraging Lonza's GS Xceed Gene Expression System, Junshi launched the first domestic antibody targeting PD-1 (Toripalimab) in China in 2018 and is now successfully advancing JS016, the first-in-class neutralizing antibody targeting SARS-CoV-2 S protein, into clinical stage in China. This powerful GS platform enabled us to fast-track CMC development from stable cell line generation to non-GMP Tox material supply to GMP clinical manufacturing.

Basel, Switzerland, 13 July 2020 - Lonza and Junshi Biosciences announced today that the first healthy volunteer has been dosed in a Phase I clinical study of JS016 at Huashan Hospital affiliated to Fudan University in China in June. JS016 is the first SARS-CoV-2 neutralizing antibody that has entered clinical trials in China and is produced using Lonza's GS Xceed Expression System. This follows on from a successful launch of the first PD-1-targeting antibody using GS Xceed last year.

At the start of the COVID-19 outbreak, Junshi Biosciences rapidly launched the research and development program focused on neutralizing antibodies using Lonza's GS Xceed expression system. Within two months, the company had completed IND enabling preclinical studies, process development and production for GLP toxicity studies, as well as the GMP production of clinical material. Junshi Biosciences is collaborating with Eli Lilly and Company to co-develop JS016 globally, with Junshi leading clinical development in Greater China and Lilly leading clinical development in the rest of the world.

The GS Xceed Expression System is Lonza's market-leading expression technology platform that includes host cell lines, vectors, and access to optimized media and feeds, as well as comprehensive methods and processes. This robust, fully integrated, scalable system can express a diverse range of biologic drugs and has an unparalleled track record of successfully taking programs from gene through cell line construction to commercial products. Together with the technical and regulatory expertise, this expression system is expected to provide valuable support for the JS016 program by helping to improve cell line development timelines and improving yields.


Lonza Group Ltd. published this content on 13 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 July 2020 13:05:00 UTC

© Publicnow 2020
All news about LONZA GROUP AG
05/10LONZA GROUP LTD : Ex-dividend day for final dividend
05/10LONZA GROUP LTD : Ex-dividend day for
05/07LONZA  : Announces Results of the 2021 Annual General Meeting - All Motions Prop..
05/07LONZA  : Specialty Ingredients to Lift Prices of Selected Products Due to Rising..
05/07LONZA  : Price Change Notification on Selected Product Portfolios
05/07LONZA  : Moderna Expects No Impact of Possible Patent Waiver on COVID-19 Vaccine..
05/07Switzerland Questions US Backing For Waiving COVID-19 Vaccine Patents
05/06LONZA  : Switzerland Secures 14 Million Doses of Moderna's Booster COVID-19 Jab
05/06Switzerland says U.S. stance on vaccine patent waiver leaves questions
05/06Switzerland says U.S. announcement on vaccine patent waiver leaves questions
More news
Sales 2021 4 980 M 5 526 M 5 526 M
Net income 2021 1 039 M 1 153 M 1 153 M
Net Debt 2021 1 371 M 1 521 M 1 521 M
P/E ratio 2021 40,9x
Yield 2021 0,55%
Capitalization 41 866 M 46 541 M 46 451 M
EV / Sales 2021 8,68x
EV / Sales 2022 7,78x
Nbr of Employees 16 540
Free-Float 99,6%
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 657,53 CHF
Last Close Price 563,60 CHF
Spread / Highest target 37,9%
Spread / Average Target 16,7%
Spread / Lowest Target -8,09%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG-0.91%46 541
MODERNA, INC.51.77%63 662
CELLTRION, INC.-25.77%33 740
SEAGEN INC.-22.39%24 668
CUREVAC N.V.30.49%21 497